Drug profile · INN
MALATHION
malathion (MALATHION) is a acetylcholinesterase inhibitor. Route of administration: topical. Current US regulatory status: approved.
malathion (MALATHION) is a acetylcholinesterase inhibitor. Route of administration: topical. Current US regulatory status: approved.
Acetylcholinesterase inhibitor
Primary target: Acetylcholinesterase
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
US 9506040
Prevascularized constructs for implantation to provide blood perfusion
US 8329753
Combination of compounds, or a bifunctional compound, that provides fatty acid metabolism and glycolysis inhibition
US 7052829
Prevascularized constructs for implantation to provide blood perfusion
US 7029838
Prevascularized contructs for implantation to provide blood perfusion
🔒 Integrated delivery networks in Middle East healthcare: what PwC says about the next phase of care
Scale creates value only when healthcare assets are connected through shared systems, referral flows and coordinated management disciplines
RYBREVANT® Access and Reimbursement Guide Overview
RYBREVANT® is indicated for specific NSCLC mutations, including EGFR exon 19 deletions, exon 21 L858R substitution mutations, and exon 20 in…
Guidance on Developing Treatments for Stimulant Use Disorders
FDA has not yet approved any medications for stimulant use disorders.
malathion (MALATHION) is a acetylcholinesterase inhibitor. Route of administration: topical. Current US regulatory status: approved.
MALATHION is a marketed brand name for malathion. Check FDA Drugs@FDA for the current US label holder and prescribing information.
malathion has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.